AbbVie购买Nimble 治疗药物, AbbVie buys Nimble Therapeutics for $200M to expand its autoimmune disease drug offerings.

AbbVie正在以2亿美元购买Nimble治疗药物,以加强其免疫药物管道。 AbbVie is acquiring Nimble Therapeutics for $200 million to enhance its immunology drug pipeline. Nimble是生物技术,侧重于对自发免疫性疾病的口服peptide治疗。 Nimble拥有一种Psorpic和IBD的临床前IL23R抑制剂。 Nimble, a biotech focused on oral peptide treatments for autoimmune diseases, has a preclinical IL23R inhibitor for psoriasis and IBD. 交易包括Nimble的合成技术和基于里程碑的潜在额外付款. The deal includes Nimble's peptide synthesis technology and potential additional payments based on milestones. 预计该交易将在2025年初结束,但须经监管批准。 The transaction, subject to regulatory approval, is expected to close in early 2025.